ATS2014:新規LABA・・・Abediterol (LAS100977)

e0156318_22274031.jpg


 今回のATSでは、LABAのAbediterol(LAS100977)の演題がかなり多いようです。インダカテロールに次ぐ新規LABAとして期待されています。Beierらのポスター発表によれば、早期に効果を発揮する作用もあり、SMART療法のような効果が期待されるとしています。
 ただ、個人的な意見としてはLABAにはレスキューの臨床的意義があるかどうかは保留の立場です。

S. Ruiz, et al.
Pharmacokinetics, Safety And Tolerability Of Fixed- And Free-dose Combinations Of Abediterol And Mometasone Furoate In Healthy Subjects: A Phase I Crossover Study
[Publication Number: A1303]

M. Miralpeix, et al.
Abediterol (LAS100977) Is A Potent And Selective β2-Agonist With Sustained Duration Of Action And Favourable Selectivity In Vitro
[Publication Number: A1304]

P. Kruger, et al.
In Vitro Dose Proportionality Of Six Abediterol (LAS100977) Formulations Used In Two Dose-Ranging Clinical Studies, One In Asthma And One In COPD
[Publication Number: A1305]

A. Gavalda, et al.
Abediterol (LAS100977), A Novel Inhaled Long-Acting β2-Agonist, With Improved Benefit/Risk Ratio In Beagle Dogs
[Publication Number: A1306]

J. Beier, et al.
Efficacy, Safety And Tolerability Of Abediterol In Stable Asthma: A 7-Day, Phase II Crossover Study
[Publication Number: A1307]

J. Beier, et al.
Efficacy, Safety And Tolerability Of Abediterol (LAS100977), A Novel Long Acting β2-Adrenergic Agonist, In Patients With Persistent Asthma
[Publication Number: A1308]

by otowelt | 2014-05-19 02:04 | 気管支喘息・COPD

<< ATS2014:気管支喘息に対... ATS2014:気管支喘息にお... >>